Company: DMAAR
Filing Date: 2025-01-14
Form Type: POS AM
Source: 0001213900-25-003137
Chunk: 22

Company: Drugs Made In America Acquisition Corp.
Filing Date: 2025-01-14
Form: POS AM
Chunk 22
---
 $4,000,000 in a private placement that will occur simultaneously with the closing of this offering. They have also agreed that if the over -allotmentoption is exercised by the underwriters in full or in part, they and/or their designees will purchase from us an additional number of private units (up to a maximum of 30,000 private units at $10.00 per private unit) in order to maintain in the trust account $10.05 per unit sold to the public in this offering. These additional private units will be purchased in a private placement that will occur simultaneously with the purchase of units resulting from the exercise of the 8 over -allotmentoption. The proceeds from the private placement of the private units will be added to the proceeds of this offering and placed in a U.S. -basedtrust account established by VStock Transfer, LLC, our transfer agent and maintained by Wilmington Trust, National Association acting as trustee. If we do not complete an initial business combination within 15 months from the closing of this offering (or up to 21 months if the completion window is extended), the proceeds from the sale of the private units will be included in the liquidating distribution to our public shareholders and the private units will be worthless. Additional Financing We have not selected any specific business combination target but intend to target businesses with enterprise values that are greater than what we could acquire with the net proceeds of this offering and the sale of the private units. As a result, if the cash portion of the purchase price exceeds the amount available from the trust account, net of amounts needed to satisfy any redemption by public shareholders, we may be required to seek additional financing to complete such proposed initial business combination. Such additional financing may be in the form of a private investment in a public entity (“PIPE”), which may be in the form of an equity, debt or convertible debt transactions. These financing transactions would be designed to ensure a return on investment to the investor in exchange for assisting the company in completing the business combination or providing sufficient liquidity to the post -combinationcompany. The price of the shares we issue may therefore be less, and potentially significantly less, than the market price for our shares at such time. Any such issuances of equity securities could dilute the interests of our existing shareholders. These financing transactions may be significantly dilutive to the post -combinationcompany, and represent the type of financing risk that is not associated with traditional initial public offerings. We cannot assure you that financing will be available to us on acceptable terms, if at